About iCDP Summit
Welcome to the 5th International Cannabinoid-Derived Pharmaceuticals Summit
The 5th International Cannabinoid-Derived Pharmaceuticals Summit brings together drug developers working on the complex production of both plant-based, biosynthetic and synthetic endocannabinoid system modulators. An elite faculty of speakers will present on crucial topics such as rigorous clinical trial data exchange, and guide discussion through vital non-clinical focus points such as IP and funding strategy – as well as cutting edge insights from the academic world. Meet face-to-face with decision-makers from the likes of Jazz Pharmaceuticals Greenwich Biosciences, ACHEM, Cannvalate, Cannabics Pharmaceuticals, Oxford Cannabinoid Technologies and many more at the first physical cannabinoid conference of the year.
What’s new for 2022?
- The lack of human evidence for the mechanism of action for cannabinoids major and minor in different therapeutic areas – led by Anthony Almada from Imaginutrition and other key stakeholders
- The wealth of RWE that can be utilised in a way that could uncover further potential for cannabinoid therapeutics with Jeff Chen, Radicle
- For the first time ever, an MP from UK government will discuss the ins and outs of drug reform in the UK and the current roadblocks
5 Reasons to Join Us This Year
Our new two-stream agenda offers more content and greater depth than ever before with over 35+ speakers and two workshops on OTC cannabinoids and Psychedelics. It’s our most comprehensive agenda to date!
Refine your preclinical research process with case study-led presentations from two industry-leading specialists, Hunter Land (Alterola Biotech Inc.) & Melanie Kelly (Tetra Biopharma)
Get an update on where the best quality cannabinoids are coming from, including synthetic, biosynthetic and plant-based sources with Purisys, Aphios and Inmed
Design robust clinical trials at all phases by joining Cannvalate for an interactive session focused on phases 2 and 3
Find collaborators and partners that will enable you to take your research to the next level, with the largest audience of pharmaceutically-focused cannabinoid specialists
